Early activation markers of human peripheral dendritic cells.
Two major populations of dendritic cells (DCs), myeloid and plasmacytoid, can be isolated from human peripheral blood, and are distinguished by differential expression of the cell surface markers CD11c and CD123. These two populations of DCs also are different in their expression of Toll-like receptor (TLRs), which are involved in their activation. To investigate the early events during activation of peripheral DCs, the cells were stimulated in vitro with ligands for TLR-4 (as in lipopolysaccharides [LPS]) or TLR-9 (CpG-containing oligonucleotide [CpG]). The earliest change in protein expression detected after stimulating peripheral DCs with lipopolysaccharide (LPS) or CpG was increased production of the chemokine interleukin (IL)-8. Enhanced production of IL-8 occurred already within 2 hours of stimulation in both myeloid dendritic cells (M-DCs) and plasmacytoid dendritic cells (P-DCs), and preceded expression of the well established activation marker CD40. Although both populations of DCs secreted IL-8 upon activation, the levels of IL-8 produced was several times higher within the M-DCs compared with the P-DCs population. Before activation, both subsets of DCs expressed the IL-8 receptor type B (CD128b); but after stimulation the IL-8 receptor was down-regulated in both populations of DCs. Increased expression of MHC class II molecules is generally regarded as an early activation marker of DCs. However, only the P-DCs showed a significant up-regulation of MHC class II after stimulation. The M-DC population up-regulated MHC class II without any prior activation; thus care should be taken using increased expression of MHC class II molecules as an early activation marker of peripheral M-DCs after activation in vitro. In conclusion, we propose that during activation of human DCs the production of IL-8 and loss of CD128b are the earliest signs of activation preceding both MHC class II, CD40, CD80, and CD86 expression.
Hellman
Peter
P
Department of Biomedical Laboratory Science, Health and Society, Malmö University, S-20506 Malmö, Sweden.
Eriksson
Håkan
H
D015703:Antigens, CD / Q000032:analysis / Q000378:metabolism*; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen / Q000378:metabolism; D039521:CD11c Antigen / Q000032:analysis; D019013:CD40 Antigens / Q000378:metabolism; D018899:CpG Islands / Q000235:genetics; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D006681:HLA-D Antigens / Q000378:metabolism; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D016898:Interferon-alpha / Q000378:metabolism; D053650:Interleukin-3 Receptor alpha Subunit / Q000032:analysis; D016209:Interleukin-8 / Q000378:metabolism*; D007378:Interleukins / Q000378:metabolism; D007700:Kinetics; D008070:Lipopolysaccharides / Q000494:pharmacology; D009838:Oligodeoxyribonucleotides / Q000235:genetics / Q000494:pharmacology; D016185:Receptors, Interleukin-3 / Q000032:analysis; D023063:Receptors, Interleukin-8B / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D015703:Antigens, CD; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D039521:CD11c Antigen; D019013:CD40 Antigens; D006681:HLA-D Antigens; D015395:Histocompatibility Antigens Class I; C115022:IL3RA protein, human; D016898:Interferon-alpha; D053650:Interleukin-3 Receptor alpha Subunit; D016209:Interleukin-8; D007378:Interleukins; D008070:Lipopolysaccharides; D009838:Oligodeoxyribonucleotides; D016185:Receptors, Interleukin-3; D023063:Receptors, Interleukin-8B; D014409:Tumor Necrosis Factor-alpha